The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

This is “bigger” than the ChatGPT moment, Lieberman wrote to me. “But Pandora’s Box hasn’t been opened for the rest of the ...

Ushikuvirus is a newly identified giant virus that infects amoebas, adding to a growing group of oversized viruses that scientists believe may have played an important role in the emergence of complex ...

Duchenne: Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026; SGT-003 continues to be generally well ...

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...

REGENXBIO Inc. (Nasdaq: RGNX) highlighted progress and upcoming anticipated milestones across its pipeline of AAV gene therapies for rare and retinal diseases. "2026 is set to be a transformative year ...

Avista Therapeutics, a preclinical gene therapy company built on deep clinical, computational and gene therapy expertise, today announced the significant expansion of its gene therapy platform.

Now, Gilead has conducted an analysis of a phenomenon that can undermine all infectious disease therapies, including ...

The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening diseaseNORWICH, England & ...

Everyone in tech agrees we’re in a bubble. They just can’t agree on what it looks like — or what happens when it pops. MIT Technology Review Explains: Let our writers untangle the complex, messy world ...